Dr Stephen Collingwood
Dr Steve Collingwood obtained his first degree in chemistry from the University of Durham and his PhD in organic chemistry from the University of Newcastle. After postdoctoral research at the University of Oxford, he joined the central research laboratories of Ciba Geigy, which later became Novartis. In 1997 he joined the Novartis respiratory disease team. During his time there, he led the chemistry on multiple respiratory projects, delivering several clinical candidates and contributing to two successful human proof of concept studies. In 2006 his contributions were recognised with a Novartis Leading Scientist award. He later became Director of Respiratory Medicinal Chemistry and a member of the Novartis Respiratory Disease Area Board. In 2014 he joined Janssen as Head of Chemistry for the respiratory research activities at its Respivert subsidiary, where he led a new research project and oversaw the inhaled DMPK strategy and Respivert IP portfolio. Throughout his time in respiratory research Steve has a particular interest in the design of novel inhaled medicines. He is an author of over 70 patents and publications.